Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study.
Sao Paulo Med J
; 140(3): 372-377, 2022.
Article
in English
| MEDLINE | ID: covidwho-1833818
ABSTRACT
BACKGROUND:
Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey.OBJECTIVE:
To determine the side effects of favipiravir and whether it is a good treatment option. DESIGN ANDSETTING:
Retrospective study conducted in Atatürk Chest Diseases and Chest Surgery Training and Research Hospital, Ankara, Turkey.METHODS:
357 patients who completed favipiravir treatment at the recommended dose were included. 37 patients with drug side effects and 320 patients without drug side effects were examined in two groups.RESULTS:
Side effects were observed in 37 (10.36%) out of 357 patients using favipiravir. The most common side effect was liver dysfunction, in 26 (7.28%) of the patients. The following other side effects were also observed diarrhea (1.4%), nausea (0.84%), abdominal pain (0.28%) and thrombocytopenia (0.28%). One patient (0.28%) presented both increased transaminases and nausea.CONCLUSION:
In this study, it was determined that favipiravir may constitute an alternative for treating COVID-19 pneumonia given that its side effects are generally well tolerated and not serious.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug-Related Side Effects and Adverse Reactions
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Sao Paulo Med J
Journal subject:
Medicine
Year:
2022
Document Type:
Article
Affiliation country:
1516-3180.2021.0489.R1.13082021
Similar
MEDLINE
...
LILACS
LIS